Orchestra BioMed Inc. (OBIO)
Orchestra BioMed Statistics
Share Statistics
Orchestra BioMed has 38.31M shares outstanding. The number of shares has increased by 6.22% in one year.
| Shares Outstanding | 38.31M |
| Shares Change (YoY) | 6.22% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 49.81% |
| Shares Floating | 26.63M |
| Failed to Deliver (FTD) Shares | 48 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -2.41 and the forward PE ratio is -1.66. Orchestra BioMed's PEG ratio is -0.2.
| PE Ratio | -2.41 |
| Forward PE | -1.66 |
| PS Ratio | 55.83 |
| Forward PS | 5.9 |
| PB Ratio | 4.47 |
| P/FCF Ratio | -2.9 |
| PEG Ratio | -0.2 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Orchestra BioMed.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.27, with a Debt / Equity ratio of 0.07.
| Current Ratio | 4.27 |
| Quick Ratio | 4.26 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $37.69K |
| Profits Per Employee | $-871.77K |
| Employee Count | 70 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 1.18 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -36.45% in the last 52 weeks. The beta is 0.62, so Orchestra BioMed's price volatility has been higher than the market average.
| Beta | 0.62 |
| 52-Week Price Change | -36.45% |
| 50-Day Moving Average | 3.94 |
| 200-Day Moving Average | 5.33 |
| Relative Strength Index (RSI) | 38.5 |
| Average Volume (20 Days) | 298.35K |
Income Statement
In the last 12 months, Orchestra BioMed had revenue of 2.64M and earned -61.02M in profits. Earnings per share was -1.66.
| Revenue | 2.64M |
| Gross Profit | 2.43M |
| Operating Income | -64.3M |
| Net Income | -61.02M |
| EBITDA | -64.3M |
| EBIT | -64.3M |
| Earnings Per Share (EPS) | -1.66 |
Balance Sheet
The company has 22.26M in cash and 2.24M in debt, giving a net cash position of 20.02M.
| Cash & Cash Equivalents | 22.26M |
| Total Debt | 2.24M |
| Net Cash | 20.02M |
| Retained Earnings | -309.88M |
| Total Assets | 76.17M |
| Working Capital | 52.96M |
Cash Flow
In the last 12 months, operating cash flow was -50.56M and capital expenditures -289K, giving a free cash flow of -50.85M.
| Operating Cash Flow | -50.56M |
| Capital Expenditures | -289K |
| Free Cash Flow | -50.85M |
| FCF Per Share | -1.38 |
Margins
Gross margin is 92.27%, with operating and profit margins of -2437.49% and -2313.27%.
| Gross Margin | 92.27% |
| Operating Margin | -2437.49% |
| Pretax Margin | -2313.27% |
| Profit Margin | -2313.27% |
| EBITDA Margin | -2437.49% |
| EBIT Margin | -2437.49% |
| FCF Margin | -1927.48% |
Dividends & Yields
OBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for OBIO is $15, which is 437.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 437.6% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -6.24 |
| Piotroski F-Score | 3 |